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Features of end-stage renal disease such as oxidative stress,
inflammation, hypertension, and dyslipidemia are associated
with accelerated atherosclerosis and increased risk of death
from cardiovascular disease. By inhibiting the formation and
increasing the disposal of oxidized lipids, HDL exerts potent
antioxidant and anti-inflammatory actions. Given that
apolipoproteinA-1 can limit atherosclerosis, we hypothesized
that an apolipoproteinA-1 mimetic peptide, 4F, may reduce
the proinflammatory properties of LDL and enhance the anti-
inflammatory properties of HDL in uremic plasma. To test
this, plasma from each of 12 stable hemodialysis patients and
age-matched control subjects was incubated with 4F or
vehicle. The isolated HDL and LDL fractions were added to
cultured human aortic endothelial cells to quantify monocyte
chemotactic activity, thus measuring their pro- or anti-
inflammatory index. The LDL from the hemodialysis patients
was more pro-inflammatory and their HDL was less anti-
inflammatory than those of the control subjects.
Pre-incubation of the plasma from the hemodialysis patients
with 4F decreased LDL pro-inflammatory activity and
enhanced HDL anti-inflammatory activity. Whether 4F or
other apolipoproteinA-1 mimetic peptides will have any
therapeutic benefit in end-stage renal disease will have to be
examined directly in clinical studies.
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Chronic kidney disease (CKD) is associated with accelerated
atherosclerosis and increased risk of death from cardiovas-
cular disease.1–4 This is primarily due to oxidative stress,
inflammation, hypertension, and dyslipidemia, which are the
common features of advanced CKD.5–11 Oxidative stress and
inflammation drive plaque formation by promoting low-
density lipoprotein (LDL) oxidation, monocyte adhesion,
infiltration, differentiation and foam cell transformation in
the artery wall, and by limiting high-density lipoprotein
(HDL)-mediated reverse cholesterol transport.12–17 HDL
protects against plaque formation and progression by
mediating reverse cholesterol transport and by exerting
potent antioxidant, anti-inflammatory and antithrombotic
actions.18–23 However, in the presence of systemic inflamma-
tion, HDL is transformed to a pro-oxidant and proinflam-
matory agent.24–26
Plasma apolipoprotein A-1 (apoA-1), the principal
apolipoprotein constituent of HDL, and HDL-cholesterol
content are significantly reduced27–32 and the antioxidant
activity of HDL is markedly impaired in patients with end-
stage renal disease (ESRD).33,34 The reduction in plasma
HDL concentration and HDL antioxidant activity can
contribute to atherogenic diathesis by limiting reverse
cholesterol transport in this population. Overexpression of
human apoA-1 (a protein comprising 243 amino acids) or
intravenous administration of apoA-I Milano has been
shown to ameliorate atherosclerosis in experimental animals
and humans.35–38 However, widespread clinical application of
apoA-1 has been hampered by its limited supplies, formid-
able cost and lack of mass-production capability. In an
attempt to overcome these limitations, a series of synthetic
short apoA-1 mimetic peptides have been developed, which
have proven to be highly effective in attenuating athero-
sclerosis in experimental animals. Comprehensive assessment
of the physical–chemical characteristics of these peptides has
revealed the critical role of the hydrophobic region in their
biological activity. Administration of the apoA-1 mimetic
peptide, 4F, has been shown to significantly improve HDL
function in mice and monkeys,39,40 reduce the size and
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macrophage content of atherosclerotic plaques in aged
mice,41,42 improve vascular function and reduce endothelial
damage in other rodents.43–45 In addition, use of apoA-1 I
mimetic peptides has been effective in a wide range of
inflammatory conditions in experimental animals.46–48 The
beneficial actions of apoA-1 I mimetic peptides are largely
related to their ability to remove oxidation products from
lipoproteins and cell membranes and restore structure and
function of LDL and HDL.45
In view of the documented LDL and HDL abnormalities
in CKD and demonstrated efficacy of apoA-1 I mimetic
peptides in experimental animals, we hypothesized that
ApoA-1 I mimetic peptide may reduce the proinflammatory
properties of LDL and enhance anti-inflammatory properties
of HDL in uremic plasma. To test this hypothesis, plasma
from 12 ESRD patients and 12 control individuals were
treated with 4F or vehicle, HDL and LDL fractions were then
isolated and added to cultures of human aortic endothelial




General data are shown in Table 1. The ESRD group showed
marked elevations of plasma creatinine and urea nitrogen
and a significant reduction of blood hemoglobin and plasma
HDL-cholesterol level and a moderate reduction of total
cholesterol concentration.
Markers of oxidative stress and inflammation
The ESRD group showed marked elevations of plasma,
tumor necrosis factor-a, interleukin (IL)-6, and IL-8 (Table 2)
and significant increases in plasma malondialdehyde (MDA)
and carbonylated proteins (Table 2), pointing to the presence
of systemic oxidative stress and inflammation.
ApoA-I, LCAT, and antioxidant enzymes
The reduction of HDL-cholesterol level was accompanied by
a marked reduction of serum apoA-1 and lecithin:cholesterol
acyltransferase (LCAT) concentrations (Table 3). This was
also accompanied by significant reductions of plasma
paraoxonase and glutathione peroxidase (GPX) activities in
the ESRD group (Table 3).
HDL antioxidant activity
As expected, addition of normal HDL lowered the pro-
oxidant activity of the standard oxidized LDL substrate used
in this assay. In contrast, HDL from ESRD patients failed to
lower the pro-oxidant activity of the standard oxidized LDL,
and on average increased it (Figure 1).
LDL and HDL inflammatory activity
Low-density lipoprotein isolated from the ERSD patients was
markedly proinflammatory compared with LDL isolated
from the control group (Figure 2). Treatment of ERSD
plasma in vitro with the apoA-1 mimetic peptide 4F
significantly reduced the inflammatory properties of the
ERSD LDL (Figure 2).
High-density lipoprotein isolated from ERSD plasma was
highly proinflammatory and was markedly less proinflam-
matory after treatment of the ERSD plasma with 4F in vitro
(Figure 3). HDL isolated from ERSD plasma was proin-
flammatory in both diabetic and non-diabetic patients (data
not shown), suggesting a dominant role of ESRD. To
determine the effect of L-4F on HDL-inflammatory index
of normal individuals, we prepared plasma from an
additional group of 10 normal healthy individuals (five male
and five female, aged 47±11.7 years). These samples were
sham treated or treated with L-4F in vitro and the HDL-
inflammatory index was determined as described in Materials
and Methods. As shown in Figure 4, the untreated HDL in
these normal healthy individuals was anti-inflammatory
Table 1 | Age, gender, serum creatinine, urea nitrogen, total
cholesterol, HDL-cholesterol, and Hgb concentrations in the




Creatinine (mg per 100ml) 0.8±0.1 8.81±0.65***
BUN (mg per 100ml) 13±0.8 68.3±4.1***
Hgb (g per 100ml) 14.4±0.41 11.1±0.33***
Total cholesterol (mg per 100ml) 160±1.6 137±6.6
HDL-cholesterol (mg per 100ml) 46.6±2.4 38.0±1.7*
Kt/V NA 1.54±0.06
BUN, blood urea nitrogen; ESRD, end-stage renal disease; HDL, high-density
lipoprotein; Hgb, blood hemoglobin; NA, not applicable.
*Po0.05, ***Po0.005.
Table 2 | Plasma concentrations of MDA, protein carbonyl,
IL6, IL-8, and TNF-a in the ESRD and control groups
Control ESRD
MDA (mmol/l) 1.09±0.09 1.87±0.07***
Protein carbonyl content (nmol/mg) 0.49±0.82 10.8±3.3*
IL-6 (pg/ml) 1.43±0.36 5.80±1.4*
TNF-a (pg/ml) 2.01±0.33 10.64 ±1.4***
IL-8 (pg/ml) 1.87±0.38 5.70±0.34***
ESRD, end-stage renal disease; IL, interleukin; MDA, malondialdehyde; TNF-a, tumor
necrosis factor.
*Po0.05, ***Po0.005.
Table 3 | Plasma concentrations of apo-A1 and LCAT and
activities of paraoxonase and GPX in the ESRD and control
groups
Control ESRD
ApoA-I (nmol/mg) 158.2±30.3 72.2±7.6*
LCAT (pg/ml) 7.6±0.47 4.7±0.54***
Paraoxonase activity (pg/ml) 143.1±17.3 91.2±7.4*
GPX activity (pg/ml) 531.0±63.7 227.5±13.4***
ESRD, end-stage renal disease; ApoA-1, apolipoprotein-A1; GPX, glutathione
peroxidase; LCAT, lecithin cholesterol acyltransferase.
*Po0.05, ***Po0.005.
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(HDL-inflammatory index¼ 0.43±0.05) and was rendered
more anti-inflammatory after treatment with L-4F in vitro
(HDL-inflammatory index¼ 0.20±0.04).
DISCUSSION
As expected plasma HDL-cholesterol concentration was
significantly reduced in ESRD patients as compared with
that found in the control group. This was associated with
marked reductions of plasma apoA-1 and LCAT concentra-
tions. LCAT is a key HDL-associated enzyme, which catalyzes
conversion of cell-derived free cholesterol to cholesterol ester
on the surface of HDL. This process depends on the dual
function of LCAT as phopholipase-2, which catalyzes
hydrolysis and release of the SN-2 fatty acid in the
phospholipid molecule, and as Acyl-CoA cholesterol
acyltransferase, which catalyzes esterification of free choles-
terol with the fatty acid generated by the latter reaction.49
LCAT-mediated conversion of amphipathic-free cholesterol
to hydrophobic cholesterol ester results in the shift of
cholesterol from the surface into the core of HDL. This
process is critical for maintaining favorable gradient for
maximal uptake of cholesterol by HDL, maturation of lipid-
poor nascent HDL to cholesterol ester-rich HDL-2, and
efficiency of reverse cholesterol transport. Thus, the observed
LCAT deficiency contributes to diminished HDL-cholesterol
content, impaired HDL maturation, and defective reverse
cholesterol transport in patients with advanced CKD. The
reduction of plasma LCAT concentration found in the ESRD
patients used in this study extends the findings of earlier
studies, which showed diminished plasma LCAT enzymatic
activity in ESRD patients50–53 and downregulation of hepatic

























Figure 1 |High-density lipoprotein antioxidative capacity in
the normal control and ESRD groups. Oxidized LDL (25ml,
250mg/ml) was incubated at room temperature for 2 h alone
(Ox-LDL) or together with HDL from control individuals and ESRD
patients. Fluorescence intensity was determined after 2 h of
incubation at room temperature as described in the Materials and
Methods section. *Po0.005 ESRD versus control HDL. CTL,

























Figure 2 | The inflammatory index determined after addition
of LDL was significantly improved after treatment with apoA-I
mimetic peptides. The values for the monocyte chemotactic
activity obtained with the control LDL (diamonds) were
normalized to 1.0 and used as the basis for expression of values
obtained with the patients’ vehicle- (squares) or L-4F-treated





























Figure 3 |HDL-inflammatory index (HII) was significantly
improved after treatment with ApoA-I mimetic peptides. The
values for the monocyte chemotactic activity obtained with the
control LDL (diamonds) were normalized to 1.0 and used as the
basis for expression of activity obtained with LDL plus the
patients’ vehicle- (squares) or L-4F-treated (circles) HDL. Po0.005






















Figure 4 | L-4F improves the HDL-inflammatory index of
normal plasma. Plasma was obtained from 10 normal healthy
individuals aged 47.2±11.7 years (five male and five female
individuals) and was sham-treated or treated with L-4F and the
HDL-inflammatory index was determined as described in the
Materials and Methods section.
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The reduction in HDL concentration in the ESRD group
was compounded by severe reduction of its antioxidant
capacity confirming recent studies.33,34 This was associated
with marked reduction of paraoxonase and GPX enzyme
activity in the study population. Paraoxonase and GPX are
major HDL-associated antioxidant enzymes that catalyze
reduction of oxidized lipids and hydroperoxides, and as such
their deficiency contributes to impaired antioxidant capacity
of HDL in ESRD patients. In addition, acquired LCAT
deficiency in ESRD can contribute to reduction of HDL
antioxidant capacity. This is because by hydrolysis of SN-2
fatty acids, LCAT removes oxidized fatty acids in oxidatively
modified phospholipids, which could otherwise initiate/
sustain oxidation-chain reaction and exert proinflammatory
and platelet-activating factor-like activity.
The ESRD group showed a marked reduction of HDL
anti-inflammatory activity as evidenced by impaired HDL-
mediated inhibition of LDL-induced monocyte chemotactic
activity. The observed defect cannot be attributed to low
plasma HDL level in the ESRD group, as equal amounts of
isolated HDL were used in these in vitro experiments.
Consequently, the observed HDL dysfunction must be due,
primarily to qualitative abnormalities. Systemic inflamma-
tion has been shown to lower antioxidant and anti-
inflammatory activity of HDL and transform HDL to a
pro-oxidant, proinflammatory agent known as acute-phase
HDL.24–26 Oxidative stress and inflammation are nearly
constant features of advanced CKD,6,8–10 as evidenced by
increased levels of inflammatory mediators (IL-6, IL-8, and
tumor necrosis factor-a) and markers of oxidative stress
(Protein carbonyls and MDA) in the ESRD patients used
here. The prevailing inflammatory state likely contributes to
the observed reduction of HDL anti-inflammatory function
in the ESRD population. This could lead to a vicious cycle in
which the underlying inflammation and oxidative stress
induce HDL dysfunction and are aggravated by it. In
addition to uptake of surplus cholesterol, HDL removes
intact and oxidized phospholipids from the macrophages and
resident cells in the artery wall.53,54 Consequently, HDL
carries the bulk of oxidized phospholipids and lipoperoxides
in the plasma55 for enzymatic processing and ultimate
disposal in the liver. Oxidized phospholipids and lipoper-
oxides participate in a vicious cycle of oxidative stress and
inflammation through lipid peroxidation chain reaction and
activation of lectin-like oxidized LDL receptor, scavenger
receptor A-1, and oxidized phospholipid receptor.56–59
Consequently by uptake, processing and disposal of lipoper-
oxides, and oxidized phospholipids, HDL plays an important
role in mitigating oxidative stress and inflammation.
However when present, systemic inflammation leads to
inactivation of the HDL-associated antioxidant enzymes
and dramatic increase in the HDL burden of oxidized lipids
and modified proteins. These modifications result in marked
reduction of HDL antioxidant and anti-inflammatory
capacity and even its conversion to a proinflammatory
agent.24–26 In addition, modification of apoA-1 by reactive
oxygen species impairs its interaction with ATP-binding
cassette transporter A-1 (ABCA-1) and thereby diminishes
HDL-mediated cholesterol efflux.60
The ESRD patients showed a marked increase in
proinflammatory activity of LDL, compounding the effects
of the associated HDL deficiency and dysfunction. This
phenomenon is most likely due to previously demonstrated
elevation of plasma level of oxidized LDL in this popula-
tion.6,8,10 Increased LDL oxidation in ESRD maybe caused by
the prevailing oxidative stress and triglyceride enrichment of
LDL, which heightens its vulnerability to oxidation. Trigly-
ceride enrichment of LDL in chronic renal failure is due to
lipoprotein lipase and hepatic lipase deficiencies, which lead
to impaired VLDL metabolism and formation of oxidation-
prone, triglyceride-rich LDL particles in humans and
experimental animals.61,62 Increased lipoprotein oxidation
and impaired HDL function and structure are coupled with
upregulation of influx pathway and accumulation of lipids in
the arterial wall of animals with CKD.63
Treatment of plasma samples from the ESRD patients with
the potent apoA-1 mimetic peptide, 4F, resulted in a marked
increase in HDL anti-inflammatory activity and significant
reduction of LDL proinflammatory activity. Although the
improvement following 4F treatment was highly significant,
treatment of most samples failed to return the values
completely to normal. As shown in Figure 4, HDL from
normal healthy donors was anti-inflammatory and was even
more anti-inflammatory after treatment with L-4F in vitro.
The HDL-inflammatory index values in the sham-treated
plasma from ERSD patients were on the order 2–3; after
L-4F treatment the values for the ERSD patients were
on the order of 1.5–2.0. This dramatically contrasts with the
normal healthy individuals who had HDL-inflammatory
index values of B0.4 with sham treatment and B0.2 with
L-4F treatment. Thus, L-4F treatment in vitro was effective in
both ERSD and normal plasma despite markedly different
HDL-inflammatory properties. This suggests that L-4F
treatment is removing or inactivating substances that are
present in both plasmas but is likely present in higher
concentrations in the ERSD patients. The most likely
candidates for these substances are proinflammatory oxidized
lipids.64
4F is an amphipathic 18-amino acid apoA-1 mimetic
peptide, which is active at nanomolar concentrations in the
presence of large molar concentrations of apoA-1 in vivo.
Detailed study of the physical–chemical characteristics of the
apoA-1 mimetic peptides has illustrated the critical role of
the hydrophobic region of the peptide in its bioactivity. The
favorable effects of the apoA-1 mimetic peptide are mediated
by its remarkable ability to preferentially remove oxidation
products from lipoproteins and cell membranes and thereby
restore HDL and LDL function and structure, improve cell
function, and attenuate inflammation.45,64 ApoA-1 mimetic
peptides have been shown to reduce atherosclerosis
and attenuate inflammation in experimental animals
without significantly changing plasma lipid levels.45 These
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observations illustrate that the anti-inflammatory properties
of HDL are as important as the levels of HDL-cholesterol and
that strategies aimed at improving HDL function may be
effective in the treatment of atherosclerosis and other chronic
inflammatory conditions.
In conclusion, oxidative stress and inflammation in ESRD
are associated with marked reduction of HDL antioxidant/
anti-inflammatory activities and heightened LDL proinflam-
matory properties. In vitro, these abnormalities were greatly
improved by treatment with the apoA-1 mimetic peptide, 4F.
Clinical studies are needed to explore the efficacy of 4F
therapy in ESRD patients.
MATERIAL AND METHODS
Patients
The study protocol was approved by the Institutional Review
Board of the University of California, Irvine and completed
with the assistance of the University of California, Irvine
General Clinical Research Center. Written informed consent
was obtained from all participants.
Twelve stable patients with ESRD maintained on hemo-
dialysis for a minimum of 3 months at the dialysis center of
University of California, Irvine Medical Center were recruited
for the study. Hemodialysis therapy was performed thrice
weekly using cellulose triacetate dialyzers. Individuals with
evidence of acute or chronic infection, or acute intercurrent
illnesses were excluded. Among the study patients, three were
receiving HMG-CoA reductase inhibitors and two were
receiving either an AT1 receptor blocker or an ACE inhibitor.
All patients were receiving phosphate binders and multi-
vitamin preparations.
Control group
A group of 12 normal age-matched control individuals served
as controls. Individuals exhibiting acute or chronic infection,
acute intercurrent illnesses, hypertension, diabetes, malig-
nancy, psychiatric disorders, or those requiring medications
were excluded.
Blood collection
Blood samples were obtained by venipuncture in the
control group and from the vascular access before initiation
of dialysis procedure in the ESRD patients. Samples
were collected in heparinized tubes and centrifuged
immediately, plasma was separated and processed for various
assays.
HDL isolation for assays without cells
High-density lipoprotein-containing supernatants were pre-
pared by removal of the apolipoprotein B-containing
proteins as described earlier.22,33,34 Briefly, 200 ml of plasma
were incubated with 40 ml of the Magnetic Bead Reagent
(Polymedco Inc., Chicago, IL) at room temperature for 5 min
with gentle mixing. The mixture was placed on the magnetic
particle concentrator for 3 min and the HDL-containing
supernatant was removed. The HDL-cholesterol content was
measured by a colorimetric assay (Thermo Electron Inc.,
Waltham, MA) using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, CA).
Paraoxonase activity assay
Serum paraoxonase activity was measured using an Aryles-
terase/paraxonase assay kit purchased from ZeptoMetrix Inc.
(Buffalo, NY) according to the manufacturer’s specifications.
Arylesterase activity was measured at 251C with a cuvette
path length of 1 cm. Change in absorbance was observed on a
SpectraMax M5 for a total of 80 s. Data from the first 20 s
were not included in the calculations.
Glutathione peroxidase activity
Serum GPX activity was measured using a kit purchased from
ZeptoMetrix Inc., according to the manufacturer’s specifica-
tions. GPX activity was measured at 251C with a cuvette path
length of 1 cm. Change in absorbance was observed on a
SpectraMax M5 for a total of 120 s. Data from the first 40 s
were not included in the calculations.
Apolipoprotein A-1 concentration
Apolipoprotein A-1 concentration was determined using an
ELISA kit purchased from Alpco Diagnostics (Salem, NH)
and a SpectraMax M5 plate reader as specified in the
manufacturer’s protocol.
LCAT concentration
Plasma LCAT protein concentration was determined using an
EIA kit from Alpco Diagnostics, following the manufacturer’s
protocol and a SpectraMax M5 plate reader.
HDL antioxidant activity assay
This assay is based on the ability of HDL to reverse oxidation
of LDL using 2,7-dichlorofluoresceindiacetate (H2DCFDA;
Invitrogen Inc., Carlsbad, CA, USA) and a copper-oxidized
LDL preparation (Kalen Biomedical Inc., Savage, MD).
DCFH-DA was dissolved in fresh methanol at 2.0 mg/ml
and incubated at room temperature in dark for 30 min to
release DCFH. Oxidized LDL (25 ml of a 250 mg/ml solution)
alone and a mixture of oxidized LDL plus 6.4 ml of individual
HDL samples (normalized at 100 mlg/ml) were placed in a
round-bottom, black polypropylene microtiter plate and
incubated at 371C on nutating mixer (Fisher Scientific,
Pittsburgh, PA) set at 24 r.p.m. for 1 h. DCFH solution was
then diluted 10-fold and 25 ml of this working solution was
added to each well (including to wells without lipoproteins),
mixed and incubated in dark on a nutating mixer set at
24 r.p.m 371C for 2 h. Interaction with lipid oxidation
products converts DCFH to DCF, which produces intense
fluorescence. Fluorescence intensity was determined using a
Fluorescent Plate Reader (SpectraMax M5 plate reader,
Molecular Devices) set at an excitation wavelength of
485 nm and an emission wavelength of 530 nm. A sensitivity
level of 0.1 and slit widths of 2.5 and 10 nm were used for
excitation and emission, respectively.
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Chemotactic activity assays
These assays were performed using the methods described
earlier.64,65 Plasma from ESRD patients was treated with 1 mg/
ml of L-4F or vehicle for 15 min at 371C with gentle mixing.
This concentration of L-4F (0.43 nM) was earlier found to
produce a maximal effect in vitro.64 The samples were then
filtered through 100 k spin filters. Plasma was fractionated by
fast performance liquid chromatography and LDL and HDL
containing fractions were pooled. Cultured human aortic
endothelial cells were treated with normal LDL alone, with
vehicle- or L-4F-treated patient LDL, and with normal LDL
plus vehicle- or L-4F-treated patient HDL. Briefly, a standard
control human LDL prepared by ultracentrifugation of the
plasma of a healthy volunteer was added as an internal
standard to all cultures at a concentration of 100 mg/ml
cholesterol. After 8 h, the supernatants were collected and the
monocyte chemotactic activity (which is largely due to the
activity of monocyte chemoattractant protein-1) in the
supernatant was determined as described earlier.64,65 The
values for the control internal standard LDL were normalized
to 1.0. For determination of the HDL-inflammatory index, a
standard control human HDL prepared by ultracentrifuga-
tion of the plasma of a healthy volunteer or mouse HDL
prepared by fast performance liquid chromatography was
added at 50 mg/ml cholesterol together with the control
human internal standard LDL at 100 mg/ml cholesterol.
Monocyte chemotactic activity was measured as migrated
monocytes per high-powered field, in triplicates in six
separate fields, after incubation of the endothelial cells with
the lipoproteins. The value obtained by addition of the
control human internal standard LDL together with the test
HDL was divided by the monocyte chemotactic activity
obtained after adding this LDL to the endothelial cells
without HDL. In this assay, anti-inflammatory HDL results
in inflammatory index values o1.0 and proinflammatory
HDL results in inflammatory index values 41.0. For
determination of the LDL-inflammatory index, the test
LDL was added to the cells at 100 mg/ml cholesterol without
added HDL and the resulting monocyte chemotactic activity
was divided by the monocyte chemotactic activity obtained
after addition of the control human internal standard LDL at
100 mg/ml cholesterol without added HDL. In this assay, if
the test LDL induces more monocyte chemotactic activity
than the control human internal standard LDL, the
inflammatory index value will be 41.0. Conversely, if the
test LDL produces less monocyte chemotactic activity than
the control human internal standard LDL, the inflammatory
index value will be o1.0.
Protein carbonyl assay
Protein carbonyl content of plasma was measured using a kit
purchased from Cayman Chemical Inc. (Ann Arbor, MI),
following the manufacturer’s protocol. The assay is based on
the reaction between 2,4-dinitrophenylhydrazine (DNPH)
and protein carbonyls, which leads to formation of an Schiff
base. This produces the corresponding hydrazone, which can
be quantified spectrophotometrically at 360–385 nm using a
SpectraMax M5 plate reader.
Malondialdehyde assay
Plasma lipoperoxides were determined by measuring malon-
dialdehyde-thiobarbituric acid (MDA-TBA) using high-perfor-
mance liquid chromatography. Briefly, a 50ml aliquot of plasma
was mixed with 750ml of 0.44 M H3PO4, 25ml of aqueous
42 mM TBA and 45ml distilled water. The mixture was heated in
a boiling water bath for 60 min. After cooling on ice, an equal
volume, 1.5 ml of alkaline methanol (made using 50 ml
methanolþ 4.5 ml 1 N NaOH) was added and centrifuged in
a microcentrifuge for 5 min. Supernatant (50ml) was then
removed and injected into a high-performance liquid chroma-
tography (SP8700; Spectra-Physics, San Jose, CA, USA) using a
manually operated injector. An Econosphere C18 column 5mm
particle, 4.6 250 mm (Alltech Inc., Deerfield, IL, USA), and a
guard column, 3.9 2.3 mm, packed with Bondapak Corasil
C18 (37–50mm particle diameter) were used. Mobile phase was
a mixture of 50 mM phosphate buffer, pH 6.8, (600 ml) and
methanol (400 ml). The flow rate was set at 1 ml/min and was
monitored with a ultraviolet detector at 532 nm. The peak
retention time was 2.9±0.15 min. The concentration of plasma
MDA was determined by interpolation of peak area into an
SP4270 integrator (Spectra-Physics), which was calibrated with
a tetramethoxypropane standard.
Measurements of plasma cytokine concentrations
Plasma concentration of IL-6, IL-8, and tumor necrosis
factor-a were determined using Millipore 13-plex inflamma-
tory cytokine panel (Billerica, MA, USA) run on Luminex
100 IS system (Austin, TX, USA). The data were analyzed
using MiraiBio MasterPlex QT Version: 0.1.171 software
(San Francisco, CA, USA).
Data analysis
Data were analyzed with Student’s t-test using SPSS 13.5
software (Chicago, IL, USA) and expressed as mean±s.e.;
P-values less than 0.05 were considered significant.
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